SCHEMBL3800758

SCHEMBL3800758

CC(C)(C)C(=O)Nc1sc2c(c1-c1nc3ccccc3s1)CCN(Cc1ccccc1)C2

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.62
KMT2A Q03164 4/20 0.62
MEN1 O00255 3/20 0.62
CRHBP P24387 1/20 0.62
CRHR2 Q13324 1/20 0.62
APEX1 P27695 8/20 0.60
UHRF1 Q96T88 2/20 0.58
TP53 P04637 2/20 0.57
KDM4E B2RXH2 4/20 0.57
NPC1 O15118 3/20 0.57
ALDH1A1 P00352 3/20 0.57
RAB9A P51151 2/20 0.57
GAA P10253 1/20 0.57
MAPK1 P28482 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
HTT P42858 2/20 0.56
USP2 O75604 1/20 0.56
POLB P06746 1/20 0.56
RECQL P46063 1/20 0.56
BLM P54132 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1494800 0.90 APEX1 (0.73) LMNAKMT2AMEN1APEX1UHRF1
SCHEMBL1495068 0.88 APEX1 (0.64) LMNAKMT2AMEN1APEX1UHRF1
SCHEMBL3757276 0.86 MEN1 (0.64) LMNAKMT2AMEN1CRHBPCRHR2
SCHEMBL1494908 0.85 LMNA (0.59) LMNAKMT2AMEN1CRHBPCRHR2
SCHEMBL13833693 0.84 APEX1 (0.70) LMNAKMT2AMEN1APEX1UHRF1
SCHEMBL3746827 0.84 LMNA (0.60) LMNAKMT2AMEN1CRHBPCRHR2
SCHEMBL13833692 0.84 APEX1 (0.69) LMNAKMT2AMEN1APEX1UHRF1
SCHEMBL13058120 0.83 LMNA (0.57) LMNAKMT2AMEN1CRHBPCRHR2
SCHEMBL13058122 0.83 LMNA (0.57) LMNAKMT2AMEN1CRHBPCRHR2
SCHEMBL13734656 0.83 APEX1 (0.81) LMNAKMT2AMEN1APEX1UHRF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298370-A1 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF RIMONYX PHARMACEUTICALS LTD. (IL) 2010-11-25 US claimed
WO-2008020438-A2 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF RIMONYX PHARMACEUTICALS LTD (IL) 2008-02-21 WO claimed
US-20100298370-A1 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF RIMONYX PHARMACEUTICALS LTD. (IL) 2010-11-25 US disclosed
US-20100298370-A1 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF RIMONYX PHARMACEUTICALS LTD. (IL) 2010-11-25 US disclosed
US-20100298370-A1 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF RIMONYX PHARMACEUTICALS LTD. (IL) 2010-11-25 US disclosed
WO-2008020438-A2 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF RIMONYX PHARMACEUTICALS LTD (IL) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298370-A1 BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF HPSE, HDGF, HPGDS LMNA 4715/4885KMT2A 4601/4885MEN1 4716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.